This company has been marked as potentially delisted and may not be actively trading. Stellar Biotechnologies (SBOT) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock SBOT vs. AVTE, NLTX, CYBN, BIOA, VIRI, WHWK, PYRGF, ATNM, OSTX, and AADIShould you be buying Stellar Biotechnologies stock or one of its competitors? The main competitors of Stellar Biotechnologies include Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), Cybin (CYBN), BioAge Labs (BIOA), Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), PyroGenesis Canada (PYRGF), Actinium Pharmaceuticals (ATNM), OS Therapies (OSTX), and Aadi Bioscience (AADI). Stellar Biotechnologies vs. Its Competitors Aerovate Therapeutics Neoleukin Therapeutics Cybin BioAge Labs Virios Therapeutics Whitehawk Therapeutics PyroGenesis Canada Actinium Pharmaceuticals OS Therapies Aadi Bioscience Stellar Biotechnologies (NASDAQ:SBOT) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, media sentiment, valuation, profitability and analyst recommendations. Is SBOT or AVTE more profitable? Aerovate Therapeutics has a net margin of 0.00% compared to Stellar Biotechnologies' net margin of -1,782.64%. Stellar Biotechnologies' return on equity of -51.12% beat Aerovate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Stellar Biotechnologies-1,782.64% -51.12% -48.37% Aerovate Therapeutics N/A -90.19%-77.47% Do insiders and institutionals have more ownership in SBOT or AVTE? 1.7% of Stellar Biotechnologies shares are held by institutional investors. 7.8% of Stellar Biotechnologies shares are held by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media prefer SBOT or AVTE? In the previous week, Stellar Biotechnologies' average media sentiment score of 0.00 equaled Aerovate Therapeutics'average media sentiment score. Company Overall Sentiment Stellar Biotechnologies Neutral Aerovate Therapeutics Neutral Which has higher earnings and valuation, SBOT or AVTE? Stellar Biotechnologies has higher revenue and earnings than Aerovate Therapeutics. Stellar Biotechnologies is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStellar Biotechnologies$210K254.06-$5.03M-$1.76-5.69Aerovate TherapeuticsN/AN/A-$75.52M-$1.70-4.23 SummaryStellar Biotechnologies beats Aerovate Therapeutics on 5 of the 9 factors compared between the two stocks. Get Stellar Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for SBOT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SBOT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SBOT vs. The Competition Export to ExcelMetricStellar BiotechnologiesPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$53.35M$763.52M$5.47B$9.53BDividend YieldN/A4.84%4.74%4.08%P/E Ratio-5.691.3428.6723.80Price / Sales254.0625.20422.8088.29Price / CashN/A19.5635.4557.96Price / Book4.726.778.275.55Net Income-$5.03M-$4.28M$3.24B$259.03M Stellar Biotechnologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SBOTStellar BiotechnologiesN/A$10.01-1.8%N/A-41.8%$53.35M$210K-5.6925Gap DownAVTEAerovate TherapeuticsN/A$8.28-0.6%N/A-88.5%$240.00MN/A-2.7720High Trading VolumeNLTXNeoleukin TherapeuticsN/A$21.68-4.6%N/A-46.3%$203.75MN/A-6.9790CYBNCybin2.7266 of 5 stars$7.47-3.5%$85.00+1,037.9%N/A$175.51MN/A-1.7050BIOABioAge LabsN/A$4.45-1.8%N/AN/A$159.53MN/A0.00N/APositive NewsVIRIVirios TherapeuticsN/A$4.77+0.8%$5.00+4.8%+2,247.1%$91.86MN/A-17.675Upcoming EarningsWHWKWhitehawk TherapeuticsN/A$1.78-1.7%N/AN/A$83.86M$25.98M11.1340PYRGFPyroGenesis Canada0.3719 of 5 stars$0.29+0.6%N/A-53.5%$54.17M$9.14M-4.8290News CoverageGap UpATNMActinium Pharmaceuticals1.9532 of 5 stars$1.64-4.7%$4.00+143.9%-75.6%$51.16MN/A-1.1830News CoveragePositive NewsOSTXOS Therapies2.0837 of 5 stars$1.75-3.1%$18.00+931.5%N/A$49.00MN/A-2.03N/AAADIAadi Bioscience0.4783 of 5 stars$1.95+0.5%$1.67-14.5%+15.1%$48.16M$25.07M-0.8640Upcoming EarningsGap Up Related Companies and Tools Related Companies AVTE Competitors NLTX Competitors CYBN Competitors BIOA Competitors VIRI Competitors WHWK Competitors PYRGF Competitors ATNM Competitors OSTX Competitors AADI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SBOT) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredIf you saw this, you'd be scared tooMarkets may look strong—but one veteran analyst warns we’re nearing a financial breaking point. After 40+ y...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stellar Biotechnologies Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Stellar Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
